Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
05
02
2021
accepted:
13
08
2021
pubmed:
26
8
2021
medline:
22
12
2021
entrez:
25
8
2021
Statut:
ppublish
Résumé
Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors. A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation because of the potential harm of sexual dysfunction. MMR and microsatellite instability status were analyzed by immunohistochemistry and fragment length polymerase chain reaction followed by capillary electrophoresis. After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment. The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed. In MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer. Immune checkpoint inhibitors are more active in treatment-naïve patients than in patients with refractory high-grade microsatellite instability (MSI-H)/deficiency in mismatch repair (dMMR) colorectal cancer. Standard neoadjuvant chemoradiation is less effective in MSI-H/dMMR rectal cancer patients than in patients with proficient mismatch repair. A young patient with Lynch syndrome and MSI-H/dMMR locally advanced rectal cancer refused chemoradiation in order to preserve his fertility. After neoadjuvant treatment with one dose of ipilimumab and two doses of nivolumab a complete clinical and pathological response was documented. Clinical trials are needed to first establish neoadjuvant treatment with immune checkpoint inhibitors in patients with locally advanced MSI-H/dMMR rectal cancer and thereafter to evaluate organ-preservation strategies.
Sections du résumé
BACKGROUND
Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors.
MATERIAL AND METHODS
A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation because of the potential harm of sexual dysfunction. MMR and microsatellite instability status were analyzed by immunohistochemistry and fragment length polymerase chain reaction followed by capillary electrophoresis.
RESULTS
After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment. The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed.
CONCLUSION
In MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer.
KEY POINTS
Immune checkpoint inhibitors are more active in treatment-naïve patients than in patients with refractory high-grade microsatellite instability (MSI-H)/deficiency in mismatch repair (dMMR) colorectal cancer. Standard neoadjuvant chemoradiation is less effective in MSI-H/dMMR rectal cancer patients than in patients with proficient mismatch repair. A young patient with Lynch syndrome and MSI-H/dMMR locally advanced rectal cancer refused chemoradiation in order to preserve his fertility. After neoadjuvant treatment with one dose of ipilimumab and two doses of nivolumab a complete clinical and pathological response was documented. Clinical trials are needed to first establish neoadjuvant treatment with immune checkpoint inhibitors in patients with locally advanced MSI-H/dMMR rectal cancer and thereafter to evaluate organ-preservation strategies.
Identifiants
pubmed: 34431576
doi: 10.1002/onco.13955
pmc: PMC8649008
doi:
Substances chimiques
Ipilimumab
0
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2110-e2114Informations de copyright
© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Br J Cancer. 2009 Jan 27;100(2):266-73
pubmed: 19165197
Ann Surg. 2020 Apr;271(4):716-723
pubmed: 30216221
Colorectal Dis. 2017 Aug;19(8):713-722
pubmed: 28612460
JAMA Netw Open. 2020 Dec 1;3(12):e2030097
pubmed: 33326026
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Nat Rev Urol. 2011 Jan;8(1):51-7
pubmed: 21135876
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
Oncoimmunology. 2019 Sep 19;8(12):e1663108
pubmed: 31741760
Clin Cancer Res. 2020 Jul 1;26(13):3271-3279
pubmed: 32144135
Oncologist. 2020 Jan;25(1):33-45
pubmed: 31383813
Nat Genet. 2006 Jul;38(7):787-93
pubmed: 16804544
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
J Natl Compr Canc Netw. 2020 Jul;18(7):798-804
pubmed: 32634770
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Nat Med. 2020 Apr;26(4):566-576
pubmed: 32251400
N Engl J Med. 2018 Aug 23;379(8):764-773
pubmed: 30134129